GlassScriptPhysician profile
Mia Daveta
NPI 1932896586
$4,900.97
in general payments reported to CMS, 2019-2025
17 companies · $2,389 in 2025
The $2,389 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $964 · 2024: $1,548 · 2025: $2,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,693 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,692.81 |
| Education | $208.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,212.23 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $852.50 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $639.60 | 2024-2025 | Fanapt |
| Alkermes, INC. | $597.25 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $479.82 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $234.95 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $213.76 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $193.72 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $104.53 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $98.95 | 2024-2025 | Qelbree |
| Lundbeck LLC | $96.51 | 2023-2025 | Rexulti |
| Tris Pharma INC | $76.76 | 2023-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $34.17 | 2023-2024 | Loreev Xr |
| Harmony Biosciences LLC | $18.16 | 2024 | |
| Noven Therapeutics, LLC | $17.43 | 2024 | Xelstrym |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $17.18 | 2024 | |
| Sage Therapeutics, LLC | $13.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Daveta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.